Evaluation of intravitreal ranibizumab injection as a line of treatment for chronic central serous retinopathy

Abstract

Background To assess the effectiveness of ranibizumab in the treatment of chronic central serous retinopathy (CCSR). Patients and methods This prospective study included 10 eyes of 10 patients with CCSR treated by a single dose of ranibizumab injected intravitreally. After injection, the patients were re-evaluated at the second day, then after 1 week, and then monthly up to 6 months. Changes in vision and macular thickness were detected before and after injection. Results The main best-corrected visual acuity increased from 0.82±0.08 logMAR before injection to 0.56±0.09 logMAR after 3 months and to 0.24±0.09 logMAR after 6 months in patients with CCSR less than 6 months, and increased from 0.78±0.16 logMAR before injection to 0.64±0.15 logMAR after 3 months and to 0.36±0.09 logMAR after 6 months in those with CCSR more than or equal to 6 months (P<0.05). The mean central macular thickness decreased from 342±36.14 μm before injection to 252±7.02 μm after 3 months and to 204±17.13 μm after 6 months in patients with CCSR less than 6 months, and decreased from 322±51.42 μm before injection to 259±26.06 μm after 3 months and to 214±18.13 μm after 6 months (P<0.05) in those with CCSR more than or equal to 6 months. The mean age of patients was 39±9.6 years. Conclusion The use of ranibizumab for treatment CCSR was more clinically effective and generally well tolerated.

Keywords

• central macular thickness
• central serous retinopathy
• ranibizumab